Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -3.25% is 88% above its 5-year average of -28.08%, near the high end of its 5-year range (-14448.00%–14.20%).
282.74% below its 12-month average of 1.78%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 12.65%.
OPERATING MARGIN
-3.25%
OPERATING MARGIN AVG TTM
1.78%
OPERATING MARGIN AVG 3Y
-40.84%
OPERATING MARGIN AVG 5Y
-28.08%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-282.74%
CURRENT VS 3Y AVG
+92.04%
CURRENT VS 5Y AVG
+88.43%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$3.01B
Operating Margin
-3.25%
TTM Avg
1.78%
3Y Avg
-40.84%
5Y Avg
-28.08%
Market Cap
$3.06B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.09B
Operating Margin
0.00%
TTM Avg
-180.11%
3Y Avg
-313.94%
5Y Avg
-1209.42%
Market Cap
$3.09B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-93.42%
5Y Avg
-160.46%
Market Cap
$2.88B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.21B
Operating Margin
-8.00%
TTM Avg
-40.81%
3Y Avg
-286.27%
5Y Avg
-194.40%
Market Cap
$2.79B
Operating Margin
12.21%
TTM Avg
13.21%
3Y Avg
-4.78%
5Y Avg
-42.05%
Market Cap
$2.73B
Operating Margin
-1100.78%
TTM Avg
-2270.51%
3Y Avg
-1606.24%
5Y Avg
-1223.21%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.01B | -3.25% | 1.78% | -40.84% | -28.08% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.06B | 0.00% | 0.00% | 0.00% | 0.00% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | 0.00% | -180.11% | -313.94% | -1209.42% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.09B | 0.00% | 0.00% | -93.42% | -160.46% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 0.00% | 0.00% | 0.00% | 0.00% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.21B | -8.00% | -40.81% | -286.27% | -194.40% |
| TransMedics Group, Inc. (TMDX)vs › | $2.79B | 12.21% | 13.21% | -4.78% | -42.05% |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 2.44% | -4.62% | -7.21% | -5.02% |
| Precigen, Inc. (PGEN)vs › | $2.73B | -1100.78% | -2270.51% | -1606.24% | -1223.21% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.33B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
91.1%
Operating Margin
-3.3%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 12.65% |
| 2026-03-31 | -8.62% |
| 2025-12-31 | 14.20% |
| 2025-09-30 | 8.59% |
| 2025-06-30 | -17.93% |
| 2025-03-31 | -37.25% |
| 2024-12-31 | -10.70% |
| 2024-09-30 | -87.29% |
| 2024-06-30 | -162.28% |
| 2024-03-31 | -63.79% |
| 2023-12-31 | -452.23% |
| 2023-09-30 | -96.84% |
| 2023-06-30 | -1286.38% |
| 2023-03-31 | -2742.36% |
| 2022-12-31 | -2310.84% |
| 2022-09-30 | -14448.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
